Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

Stock Information for Amarin Corporation plc

Loading

Please wait while we load your information from QuoteMedia.